Better Therapeutics, Inc.

Better Therapeutics, Inc. entered the public markets through its business combination with Mountain Crest Acquisition Corp. II, a blank-check company that traded on Nasdaq under the ticker MCAD and was sponsored by Mountain Crest Capital LLC. Mountain Crest Acquisition Corp. II completed its initial public offering in 2021, targeting acquisitions in the healthcare sector. The combined company operates in the prescription digital therapeutics space, with a focus on developing software-based treatments for cardiometabolic diseases. The company filed an 8-K current report with the Securities and Exchange Commission on June 13, 2022, reflecting activity in the post-merger period. Sign up on SpacDesk for full filing data, merger timelines, and analytics on MCAD and hundreds of other SPACs.